Krishana Gopal Das
About Krishana Gopal Das
Krishana Gopal Das serves as the Head of Product Strategy for Japan, China, and Korea at ArisGlobal, where he has led significant advancements in drug safety automation. With a background in Mechanical Engineering and extensive experience in Pharmacovigilance, he has contributed to industry knowledge through publications and workshops.
Work at ArisGlobal
Krishana Gopal Das has been with ArisGlobal since 2011, currently serving as the Head of Product Strategy for Japan, China, and Korea. In this role, he leads initiatives focused on product enhancements and automation in drug safety processing. He has significantly reduced the overall safety case processing effort for Japanese pharmaceutical companies. His responsibilities include preparing and maintaining the product roadmap for the APAC region, which defines both short- and long-term product enhancements. Prior to his current position, he worked as a Senior Software Engineer at ArisGlobal from 2006 to 2010.
Education and Expertise
Krishana Gopal Das earned a Bachelor of Engineering (BE) in Mechanical Engineering from Visvesvaraya Technological University, completing his studies from 2002 to 2006. His academic background provides a strong foundation for his expertise in product strategy and automation within the pharmaceutical industry. He possesses a deep understanding of Pharmacovigilance and safety regulations, including the MHLW Green Book, ICH E2B (R2/R3), and NMPA E2B(R3) regulations.
Background
Before joining ArisGlobal, Krishana Gopal Das worked at Tata Consultancy Services as a Business Analyst from 2010 to 2011 in Bengaluru, India. His experience in this role contributed to his skills in analyzing business needs and implementing effective solutions. His career in the pharmaceutical technology sector began with his position as a Senior Software Engineer at ArisGlobal, where he worked for four years before transitioning to product strategy.
Achievements
Krishana Gopal Das has published a white paper and blog focusing on current trends in Pharmacovigilance, emphasizing the importance of automation and addressing regulatory challenges. He has also conducted workshops with pharmaceutical companies and Contract Research Organizations (CROs) to share best practices and improve compliance, quality, and productivity in drug safety processes.